Lack of inhibition strengthens nicotine addiction

March 13, 2002

Brief exposure to low levels of nicotine not only boosts the brain's 'reward' system but also blocks a rival system that limits the duration of such rewards, report University of Chicago researchers in the March 14, 2002, issue of the journal Neuron. The finding helps scientists understand why nicotine addiction takes root so quickly and lasts so long.

In 2000, a team from the same laboratory demonstrated how the first exposure to nicotine can create an enduring 'memory trace,' which instills the desire to repeat the experience and amplifies the pleasing effects of subsequent nicotine exposure. The current paper reveals how nicotine prolongs the reward period by disabling the system that counterbalances the drug's pleasant effects.

The reinforcing effect of nicotine is the primary reason people cannot quit smoking, despite widespread awareness that smoking causes cancer, heart disease, stroke, emphysema, bronchitis, vascular disease, cataracts and impotence. The World Health Organization attributes 4 million deaths each year to tobacco use.

"It would be difficult to design a better drug to promote addiction to this horrible habit," said neurobiologist Daniel McGehee, Ph.D., assistant professor in the department of anesthesia and critical care at the University of Chicago and director of the study. "It takes only a few exposures to create a lasting memory of the rewards of smoking, which are reinforced by each cigarette smoked. Now we find that nicotine also suppresses the brain's efforts to limit that pleasure."

The brain reward areas serve to acknowledge and reinforce beneficial behaviors, for example eating when you're hungry. Specialized nerve cells encourage the body to repeat pleasing behaviors by releasing dopamine, the neurotransmitter associated with pleasant feelings, into these reward areas. "That was good," is the basic message of increased dopamine levels. "Do it again."

Unfortunately, drugs of abuse such as nicotine can usurp those pathways, providing the same sort of encouragement for harmful actions such as smoking.

McGehee and his colleagues, post-doctoral researchers Huibert Mansvelder and Russel Keith, working with brain tissue from rats, demonstrated how nicotine extends the duration of these rewards.

In previous work, McGehee's team showed that nicotine produces pleasure by attaching to the nicotinic acetylcholine receptor found on certain nerve cells. In response to nicotine, these nerve cells release a chemical signal called glutamate that tells connected neurons to release dopamine. The more these nerve cells are excited, the more dopamine is released and the more pleasant the feeling.

In this paper, the researchers looked at the effects of nicotine on nerve cells that use a different chemical, called GABA, which inhibits dopamine release. These nerve cells have a slightly different version of the nicotinic acetylcholine receptor. Although they respond to the initial nicotine exposure, these receptors quickly become overwhelmed and lose their power to generate repeated releases of GABA. This renders them unable to reign in the excitation caused by nicotine. They remain disabled for up to an hour.

"As a result," said McGehee, "the reward system is turned on right away and it keeps sending reward signals for 60 minutes even though nicotine levels drop off 15 minutes after smoking. We suspect that this ability to extend the reward only enhances the drug's ability to reinforce smoking."

It may also provide a new target for drugs designed to help people stop smoking by interfering with nicotine's effects, say the authors.
The National Institute of Neurological Disorders and Stroke, the National Institute for Drug Abuse, the Brain Research Foundation and the Netherlands Organization for Scientific Research funded this study.

University of Chicago Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to